Table 1.
Baseline Characteristics Before and After Propensity Score–Weighting Adjustment
| Characteristic | Before Adjustment | After Adjustment | ||||
| Control Group (n=64) | Chemotherapy Group (n=219) | Standardized Difference | Control Group (n=36.2) | Chemotherapy Group (n=36.2) | Standardized Difference | |
| Age (y) | 57.4±11.8 | 55.1±10.4 | 0.206 | 55.9±11.3 | 55.9±11.0 | <0.001 |
| BMI (kg/m2) | 22.0±3.7 | 22.0±3.4 | 0.005 | 22.2±4.0 | 22.2±3.4 | <0.001 |
| Diabetes mellitus | 5 (7.8) | 6 (2.7) | 0.228 | 2.3 (6.4) | 2.3 (6.4) | <0.001 |
| Cardiovascular diseases | 6 (9.4) | 15 (6.8) | 0.093 | 3.1 (8.5) | 3.1 (8.5) | <0.001 |
| Use of immunosuppressant | 2 (3.1) | 5 (2.3) | 0.052 | 1.1 (2.9) | 1.1 (2.9) | <0.001 |
| Postoperative complications | 4 (6.2) | 14 (6.4) | 0.006 | 2.0 (5.5) | 2.0 (5.5) | <0.001 |
| Stage 1A | 42 (65.6) | 48 (21.9) | 0.981 | 18.2 (50.4) | 18.2 (50.4) | <0.001 |
| Stage 1C1 | 13 (20.3) | 106 (48.4) | 0.619 | 10.7 (29.6) | 10.7 (29.6) | <0.001 |
| Stage 1C2 | 7 (10.9) | 24 (11.0) | 0.001 | 5.3 (14.6) | 5.3 (14.6) | <0.001 |
| Stage 1C3 | 2 (3.1) | 41 (18.7) | 0.516 | 1.9 (5.4) | 1.9 (5.4) | <0.001 |
| Preoperative cyst size (cm) | 12.9 (6.0) | 12.3 (5.7) | 0.107 | 13.0 (5.9) | 13.0 (5.8) | <0.001 |
| Adhesions in pouch of Douglas | 39 (60.9) | 124 (56.6) | 0.088 | 21.6 (59.7) | 21.6 (59.7) | <0.001 |
| JSGO-accredited hospitals | 44 (68.8) | 106 (48.4) | 0.422 | 21.8 (60.4) | 21.8 (60.4) | <0.001 |
| Pelvic lymphadenectomy | 45 (70.3) | 167 (76.3) | 0.135 | 25.9 (71.6) | 25.9 (71.6) | <0.001 |
| Para-aortic lymphadenectomy | 41 (64.1) | 135 (61.6) | 0.05 | 22.6 (62.5) | 22.6 (62.5) | <0.001 |
| Year of surgery | 2012 | 2013 | 0.256 | 2012 | 2012 | <0.001 |
BMI, body mass index; JSGO, Japan Society of Gynecologic Oncology.
Data are mean±SD or n (%) unless otherwise specified.